| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.096 | 0.02 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.095 | 0.02 |